Navigation Links
Taxane in Medical News

Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer

...nt demographics and key ovarian cancer disease characteristics, including age, ECOG Performance Status, presence of bulky disease and history of prior taxane therapy. A greater number of patients (13, 20%) had platinum refractory disease on the TELCYTA plus PLD arm compared to (8, 13%) with the PLD arm. ...

Research Findings on Nine GlaxoSmithKline Cancer Compounds to be Presented at ASCO 2009

...tients with advanced or metastatic breast cancer whose tumors overexpress HER2/ErbB2 and who have received prior therapy including an anthracycline, a taxane and trastuzumab. On June 10, 2008, the European Commission granted a conditional marketing authorization for lapatinib in all 27 European Union (E.U.)...

Drug May Help Against Inflammatory Breast Cancer

...kin of more than two-thirds of the breast, tenderness, hardening and warming of the breast. For patients resistant to conventional anthracycline or taxane and trastuzumab, treatment options are limited. Lapatinib inhibits HER2, a protein that's expressed much more in inflammatory breast cancer than in ot...

Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer

...greed to by FDA, will assess the capacity of farletuzumab to extend progression free survival and overall survival in combination with carboplatin and taxane at two different dose levels of farletuzumab. The study will be conducted as a randomized, double-blind, placebo-controlled trial. Morphotek expects ...

Non-Hormonal Therapies Aid Breast Cancer Patients

...n overall death, compared with older single-agent chemotherapy. Single drug taxane treatment led to a relative risk reduction of 33 percent, while a combination of a taxane with capecitabine or gemcitabine led to a 51 percent relative risk reductio...

Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium

...ong North Carolina metastatic breast cancer patients treated with Xeloda or taxane monotherapy. -- Dec. 14, 7:00 to 9:00 a.m., [Poster No. 6107], Cape...urvival outcome is similar for first-line chemotherapy with capecitabine or taxane for metastatic breast cancer (Lead Author: Gretchen Kimmick) The ma...

FDA Accepts Genta's NDA Amendment as Complete Response for Genasense(R) Treatment of Chronic Lymphocytic Leukemia

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...

Also in the May 27 JNCI

...acted follow-up, the authors write. A retrospective analysis of the data failed to detect a subgroup of patients who were more likely to respond to taxane therapy on the basis of their tumors expression of the estrogen receptor and HER2. In an accompanying editorial, Clifford Hudis, M.D., and Chau Dan...

Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane, Tesetaxel

..." About Tesetaxel Tesetaxel is a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. However, bo...ule, tesetaxel was developed to maintain the high antitumor activity of the taxane drug class while eliminating infusion reactions, reducing neuropathy, and i...

New study of targeted therapies for breast cancer -- model for global clinical trials

...he treatment of advanced or metastatic HER2-positive breast cancer in patients who had received prior therapy with three agents -- an anthracycline, a taxane and Herceptin. GlaxoSmithKline is providing the study drug, as well as additional financial support for the ALTTO trial. All drugs carry potential sid...
Taxane in Medical Technology

FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral Taxane

Clinical Studies Expected to Restart in Second Half 2008 BERKELEY HEIGHTS, N.J., June 23 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced that the Company has received notification from the U.S. Food and Drug Administration (FDA) that Genta may resume c...

ADVENTRX Announces Results From ANX-514 Bioequivalence Study

...mary endpoint of the study, was not demonstrated based on benchmark regulatory standards. "Following discussions with clinicians and experts in taxane pharmacokinetics, we believe that the increased blood-levels of docetaxel, which we observed solely during the first hour of a 168-hour observation pe...

BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial

...the U.S. Tavocept Trial involved cisplatin and the taxane drug docetaxel while the Japan Tavocept Trial involved cisplatin and the taxane drug paclitaxel, BioNumerik has also now observed ...reatment regimens utilizing two different types of taxane chemotherapy drugs. "It is also important to con...

Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...

EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting

...10620/ENMDLOGO ) For this Phase 2 single agent, open label study, a total of 65 patients who had previously received at least one anthracycline and taxane therapy were enrolled. 55 patients were evaluable for tumor response. Of the evaluable patients, the antitumor activity observed with MKC-1 included 3...

ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)

...ts who are Herceptin receptor (Her2/neu) negative and who have failed prior taxane and anthracycline therapies. Data available from 31 patients indicated a 23...n in patients with advanced breast cancer who have failed anthracycline and taxane chemotherapies with clearly defined criteria. The primary endpoint for the ...

Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies

...ongly predicted benefit from treatment with docetaxel (Taxotere), a type of taxane commonly used for breast cancer therapy. A genomic classifier predicting di... biology of breast cancer and now, possibly, treatment benefit for a common taxane regimen with our ongoing study of the utility of Oncotype DX and additional...

Genasense(R) Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...

Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...

Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...
Taxane in Biological News

Common chemotherapy drug triggers fatal allergic reactions

...rse Event Report System between 1997 and 2007 with 109 (38 percent) deaths in patients who received Cremophor-based paclitaxel, a solvent-administered taxane chemotherapy. Adverse event reports generally only represent from 1 to 10 percent of actual incidence, so the number of hypersensitivity reactions...

Eribulin mesylate demonstrated anti-tumor activity in patients with advanced breast cancer

...edian of four prior chemotherapy regimens that included an anthracycline, a taxane and capecitabine. About Study 211 Study 211 is a Phase II, open-label, s...y advanced or metastatic breast cancer who had received an anthracycline, a taxane and capecitabine as prior therapy, and who were refractory to their last ch...

Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer

... Berlin, Germany: Women with a particularly aggressive form of breast cancer seem to do better if they are treated with a combined anthracycline and taxane chemotherapy regimen before surgery, together with trastuzumab (Herceptin) before and after surgery, according to results from the largest multi-centr...

Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors

...searchers now plan to investigate the effects of adjuvant and neo-adjuvant treatments in women with BRCA1/2-associated breast cancers, and to evaluate taxane and platinum therapies further. ...
Taxane in Biological Technology

Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane

Company Also Completes FDA Submission for Removal of Clinical Hold BERKELEY HEIGHTS, N.J., June 10 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced that the Company has received notice of allowances for two major patents from the European Patent Office for i...

First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer

...gle arm studies encompassing two treatment regimens (every 14 days or every 21 days). Patients include those with metastatic breast cancer with prior taxane treatment, those with metastatic, platinum-resistant ovarian cancer and those with metastatic cervical cancer. The trials are designed to evaluate th...

Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer

...he potential for additional uses of picoplatin as a combination therapy in the treatment of non-small cell lung and ovarian cancers where platinum and taxane combinations are currently used." About Picoplatin Picoplatin has an improved safety profile relative to existing platinum-based cancer therapies ...

Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same drug class as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the Uni...

Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008

...udy, performed in Serbia and Poland, MVA-BN(R)-HER2 is being evaluated following first or second-line chemotherapy or in combination with single-agent taxane chemotherapy. Both studies evaluate treatment of metastatic breast cancer patients, whose tumors overexpress HER2. Patients are vaccinated 3 times, at...

Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights

...w us to resume clinical trials with a leading oral taxane that addresses a large, well-characterized market....e proposed indication. Tesetaxel: A Leading Oral taxane with Anticancer Activity In other regulatory act...esetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same drug class as paclitaxel and d...

Genta Announces Second Quarter 2008 Financial Results and Conference Call

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same drug class as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the Uni...

Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia

...tial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi- synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...

Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs

...ntial treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the ...

Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights

...strategy -- Tesetaxel in-licensed -- leading oral taxane and new clinical-stage product -- FDA provide...s to tesetaxel has provided us with a leading oral taxane that addresses a very large and well-characterized...e efficacy and safety. Tesetaxel: A Leading Oral taxane with Anticancer Activity Tesetaxel is the latest...
Other Tags
(Date:7/12/2014)... Hills, CA (PRWEB) July 12, 2014 For ... why are bodies can readily absorb the nutrients in food. ... tiny particles that are small enough to be absorbed by ... DZ10 team, a lack of enzymes in regular food is ... is a product that was started by Michelle DelPresto, a ...
(Date:7/12/2014)... July 12, 2014 “Critical Care ... New and Late-Stage Four-Factor PCCs and Recombinant Products ... the critical care market in the US, UK, ... report provides an estimation of market size for ... covers critical care indications that are being treated ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 As reported in ... Institute of Standards and Technology), the June 25th, 2014 Supreme ... electronic discovery world. It was also met with ... depending on whether it was seen from an individual privacy ... much is fact, there is now precedent which will require ...
(Date:7/12/2014)... Dubai is buzzing with the announcement ... to the UAE. The National Basketball Association’s (NBA) ... the UAE from 28-31 October to lead the Kareem ... awareness. The event is being organized by Maven Marketing ... company based in Dubai. The announcement was made today ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Praeclarus ... Made Simple as a valuable new resource for women ... two-thirds of American women work away from their children. ... touting the benefits of breastfeeding, but often feel unsupported ... nurse their babies. With its evidence-based insights, and written ...
Breaking Medicine News(10 mins):Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2
(Date:7/10/2014)... , June 27, 2014  Pomerantz LLP has ... Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain ... United States District Court, Middle District of ... behalf of a class consisting of all persons ... securities between December 17, 2013 and May 22, ...
(Date:7/10/2014)... 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused ... Gino Pereira was interviewed on July 1 st ... Florida . Mr. Pereira discusses the company,s next generation ... and how the Wocket™ aims to replace a traditional wallet ... Cedric Harris tells Gino he has never heard of ...
(Date:7/10/2014)... July 8, 2014 Fingerprint ... new design win (DW). An Asian OEM has selected FPC1021 ... production start in August 2014.   FPC is ... which has a planned date for start of mass production ... order of SEK 5M, for delivery in the first half ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
Other Contents